(Q34701705)

4 August 2017

1 reference

title

Effects of thiazolidinediones on bone loss and fracture (English)

1 reference

4 August 2017

1 reference

Catherine E Murphy

1

1 reference

4 August 2017

Philip T Rodgers

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

16 October 2007

1 reference

Annals of Pharmacotherapy

4 August 2017

published in

1 reference

4 August 2017

volume

41

1 reference

4 August 2017

issue

12

1 reference

4 August 2017

page(s)

2014-2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

4 August 2017

cites work

1 reference

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

21 January 2018

1 reference

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase

21 January 2018

1 reference

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

21 January 2018

1 reference

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

21 January 2018

1 reference

Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).

21 January 2018

1 reference

Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice

21 January 2018

1 reference

Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients

21 January 2018

1 reference

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

Biochemical markers of bone remodeling

21 January 2018

1 reference

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone

21 January 2018

1 reference

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study

21 January 2018

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1K286

1 reference

4 August 2017

1 reference